🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GP MDI

Found 10 matching trials

Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD

PHASE2

The overall objective of this study was to assess the efficacy and safety o...

Status

Completed

Location

Pearl Investigative Site

Start Date

2015-01-28

Trial ID

NCT03256552

Treatments Being Tested

Glycopyrronium MDI 28.8 micrograms Glycopyrronium MDI 14.4 micrograms Glycopyrronium MDI 7.2 micrograms Placebo MDI

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

PHASE3

This is a multi-center, randomized, double-blind, parallel group, chronic d...

Status

Completed

Location

Pearl Investigative Site

Start Date

2013-11

Trial ID

NCT01970878

Treatments Being Tested

GFF MDI (PT 003)GP MDI (PT001)FF MDI (PT005)Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

PHASE3

To assess the effect of treatment with Glycopyronnium (GP) MDI administered...

Status

Completed

Location

Research Site

Start Date

2016-12-29

Trial ID

NCT02937584

Treatments Being Tested

GP MDI (PT001) 14.4 μg FF MDI (PT005) 9.6 μg

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

PHASE2

Study Comparing the Efficacy and Safety of PT001 to Placebo and Open-label ...

Status

Completed

Location

Research Site

Start Date

2017-12-13

Trial ID

NCT03358147

Treatments Being Tested

GP MDI 28.8 μg GP MDI 14.4 μg GP MDI 7.2 μg Placebo MDI Spiriva Respimat 2.5 μg

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

PHASE2

The purpose of this study is to evaluate the effect of 2 different GP meter...

Status

Recruiting

Location

Research Site

Start Date

2026-04-14

Trial ID

NCT07525375

Treatments Being Tested

GP MDI BFF MDI Placebo MDI

PK Study of PT003 and PT001 in Japanese Healthy Subjects

PHASE1

A Randomized, Double-Blind, Single-Dose, Four-Period, Four-Treatment, Cross...

Status

Completed

Location

SNBL

Start Date

2014-07

Trial ID

NCT02196714

Treatments Being Tested

Glycopyrronium and Formoterol Fumarate (GFF) Dose 1 Glycopyrronium and Formoterol Fumarate (GFF) Dose 2 Glycopyrronium (GP) Dose 1 Glycopyrronium (GP) Dose 2

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

PHASE3

This is a multicenter, randomized, double-blind, parallel group, chronic-do...

Status

Completed

Location

Pearl Investigative Site

Start Date

2013-07

Trial ID

NCT01854658

Treatments Being Tested

GFF MDI (PT003)GP MDI (PT001)FF MDI (PT005)Placebo

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

PHASE2

A Randomized, Double-Blind, Chronic Dosing (14 days), 5-Period, 7-Treatment...

Status

Completed

Location

Pearl Therapeutics Inc.

Start Date

2015-05-27

Trial ID

NCT02433834

Treatments Being Tested

Glycopyrronium MDI Serevent Diskus 50 μg Placebo

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

PHASE3

A chronic dosing (24 weeks) study to assess the efficacy and safety GFF MDI...

Status

Completed

Location

Research Site

Start Date

2015-03-30

Trial ID

NCT02343458

Treatments Being Tested

GFF MDI (PT003)FF MDI (PT005)GP MDI (PT001)Placebo MDI

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

PHASE3

The overall objective of this study is to assess the efficacy and safety of...

Status

Completed

Location

Pearl Investigative Site

Start Date

2013-05

Trial ID

NCT01854645

Treatments Being Tested

GFF MDI GP MDI FF MDI Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)Placebo MDI

Previous Next